Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective-Reference-Cited by-同舟云学术

Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective

Published:2019-08-04 Issue:12 Volume:22 Page:1243-1252
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Gerbasi Margaret E.¹,Stellato Daniel¹,Ghate Sameer R.²,Ndife Briana²,Moynahan Aaron¹,Mishra Dinesh³,Gunda Praveen³,Koruth Roy³,Delea Thomas E.¹

Affiliation:

1. Policy Analysis Inc. (PAI), Brookline, MA, USA;

2. Novartis Pharmaceuticals Corp, East Hanover, NJ, USA;

3. Novartis Pharmaceuticals Corp, Hyderabad, India

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1635487

Reference45 articles.

1. Therapy for metastatic melanoma: an overview and update

2. Surveillance‚ Epidemiology‚ and End Results Program. Cancer stat facts: melanoma of the skin; 2017 [cited 2017 May 1]. Available from: https://seer.cancer.gov/statfacts/html/melan.html.

3. Final Version of 2009 AJCC Melanoma Staging and Classification

4. Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies

5. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review;Value in Health Regional Issues;2023-09

2. Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma;European Journal of Dermatology;2023-04

3. Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment;PharmacoEconomics;2023-01-19

4. Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis;Gynecologic Oncology;2023-01

5. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma;Endocrine-Related Cancer;2022-06-01